4D·

Why BioNTech (BNTX) is now a buy - Fundamental & strategic arguments

Hello everyone,

Today I would like to briefly explain why I currently consider BioNTech $BNTX (+0.81%) is currently an interesting buy candidate. The share has recently been under heavy pressure, but in my view it offers an attractive risk/reward ratio, especially for medium to long-term investors.

1. fundamental valuation

The market capitalization is currently (as of July 2025) significantly below the level of the pandemic peak times, although the company continues to generate solid sales.
BioNTech has a very strong balance sheet with over € 15 bn in cash, which provides enormous financial flexibility.
The company has no significant debt, which is a clear advantage given the current interest rate environment.

2. pipeline & future prospects

BioNTech has consistently invested the proceeds from the Covid vaccines in research and development.
The cancer immunotherapy pipeline is particularly exciting with several mRNA-based approaches in clinical phases, especially in cooperation with Roche and Genentech.
BioNTech is also making progress in the area of mRNA vaccines against other infectious diseases (e.g. malaria, tuberculosis, influenza).
The mRNA technology continues to be regarded as a key platform for rapid, targeted therapy developments.

3. partnerships & strategic orientation

Collaborations with major players such as Pfizer and Genentech secure know-how, sales power and financial resources.
Expansion of production capacities, particularly in Africa, strengthens global presence and could open up additional markets in the future.

4. valuation & market psychology

The share is currently trading at a significant discount to its 2021 high.
Many investors have "written off" BioNTech after the pandemic, which opens up potential from an anti-cyclical perspective.
If only some of the cancer therapy programs are successful, this could result in significant revaluations.

Conclusion:

It may remain volatile in the short term, but in the medium to long term I see BioNTech as an exciting biotech stock with substance, an innovative pipeline and a solid financial cushion. The risk/reward ratio appears attractive - especially for investors who are patient and continue to see mRNA as a technology of the future.

I look forward to hearing your opinions - who else is invested here or is watching BioNTech?

7 Comments

Patrick Schäfer@Hotte1909

It's definitely one of the more solid "pharma" titles. Personally, however, the whole sector is getting on my nerves. One piece of bad news about some study and you're already at -15% - sometimes the companies don't even have to have bad news themselves, but are simply dragged down because xy has stopped research on something similar.

•

Chris@Multibagger

I'm with you all the way and $BNTX is my largest single position with 6% in the portfolio and will continue to be topped up with a small savings plan. I expect prices of at least €500 in the next 5 years and I assume that at least 2-3 candidates with blockbuster potential will come through.

•

Max@MaxtheCat

@Multibagger how do you come up with the 500€ or what makes you so sure? :)
BNT122 would be relatively important in terms of the study results. So I also see the chances, but the probability of success is more like 10-15%. I'd be interested to know why you rate it so highly.

•

Chris@Multibagger

@MaxtheCat I simply believe that BMS would not have invested so many billions in the joint partnership if they had not seen very good-looking interim results. And they also have a large financial cushion to push ahead with further developments. And with the coronavirus vaccine, they have already shown that they understand MRNA. I also see the acquisition of Curevac as positive.
And then, of course, there is simply a gut feeling. There are many investment opportunities in the biotech sector. All of them are a bet on the future. I have opted for $BNTX.

•

Cekay@CMustermann

@Multibagger Unfortunately, investments by German authorities are not a sign of quality... what "we" have already invested in has simply fizzled out into the ether. You can't think about it for too long

••

Chris@Multibagger

@CMustermann What do you mean by German authorities? They have no shares. The investment came from the pharmaceutical giant Bristol Meyers.

••

Jean-Poul@ArmeSocke1982

But this will not happen in the next few months / only when the studies are successful will the cash register ring until then the share price will be unstable ...plus 0.0% dividend ...think the first cancer drugs will probably be approved in early 2026

••